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Investigation of disorders of sex development (DSD) has resulted in the discovery of multiple sex-determining genes. MAP3K1 encodes a signal transduction regulator in the sex determination pathway and is emerging as one of the more common genes responsible for 46,XY DSD presenting as complete or partial gonadal dysgenesis. Clinical assessment, endocrine evaluation, and genetic analysis were performed in six individuals from four unrelated families with 46,XY DSD. All six individuals were found to have likely pathogenic MAP3K1 variants. Three of these individuals presented with complete gonadal dysgenesis, characterized by bilateral streak gonads with typical internal and external female genitalia, while the other three presented with partial gonadal dysgenesis, characterized by incomplete testicular development, resulting in clitoral hypertrophy with otherwise typical female external genitalia.
Testing for MAP3K1 variants should be considered in patients with 46,XY complete or partial gonadal dysgenesis, particularly in families with multiple members affected with 46,XY DSD.
Identification of a MAP3K1 variant should prompt an evaluation for DSD in female siblings of the proband.
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| INTRODUCTION
Disorders of sex development (DSD) are congenital conditions in which development of chromosomal, gonadal or anatomic sex is atypical and may affect up to 1:4,500 infants (Lee et al., 2006) . Some of these disorders result from errors in sex determination, the process by which the male or female gonad is formed, and include 46,XX testicular DSD, 45,X/46,XY mixed gonadal dysgenesis, ovotesticular DSD, and 46,XY DSD with partial or complete gonadal dysgenesis (Ono & Harley, 2013) . Sex determination is genetically controlled by the expression of the SRY gene on the Y chromosome, causing the undifferentiated gonad to develop into a testis (Ono & Harley, 2013) .
Sex differentiation follows when Sertoli cells in the developing testis
produce Anti-Müllerian Hormone (AMH), leading to regression of the Müllerian ducts, while production of testosterone by the Leydig cells promotes differentiation of Wolffian duct structures. In the absence of a Y chromosome and expression of SRY, the undifferentiated gonad develops as an ovary and the Wolffian ducts regress (Ono & Harley, 2013 Multiple transcription factors and signaling molecules have been discovered to influence sex determination based on the identification of chromosomal abnormalities and identification of pathogenic variants in the genes encoding these factors in subjects with DSD.
For individuals with 46,XY DSD, gonadal dysgenesis can result from loss of function mutations in SRY, NR5A1(SF1), SOX9, DHH, GATA4, and WT1, single copy expression of DMRT1, SOX 9, SF1, and WT1, or duplication of NR0B1 and WNT4 (Baxter et al., 2015; Ono & Harley, 2013) . The majority of individuals with DSD lack a known specific genetic etiology; however, more recently exome sequencing has been used to identify a likely genetic etiology in up to 43% of patients with 46,XY DSD (Baxter et al., 2015; Eggers et al., 2016) .
The signal transduction gene, MAP3K1, is part of a network of genes responsible for gonadal development. MAP3K1 mutations were first described in 2010 in two large families with 46,XY DSD and an autosomal dominant, sex-limited pattern of transmission as well as in 2 of 11 sporadic cases of 46,XY gonadal dysgenesis. In the large families that were reported, there were phenotypic presentations ranging from complete gonadal dysgenesis, sometimes with gonadoblastoma, to hypospadias and micropenis with cryptorchidism (Pearlman et al., 2010) .
Recent studies suggest that MAP3K1 is one of the more commonly mutated genes in 46,XY DSD, with mutations reported in 13-18% of patients (Ostrer, 2014) . Functional studies of MAP3K1 variants have demonstrated gain of function effects, causing increased phosphorylation of downstream targets resulting in decreased expression of SOX9, important for development of the testis, and increased expression of β-catenin. These gene expression changes mimic the signaling pathway in ovarian development and thus result in abnormal testicular development (Loke et al., 2014) . We report six individuals with heterozygous likely pathogenic MAP3K1 variants from four unrelated families causing both partial and complete gonadal dysgenesis. In one family, the presence of the MAP3K1 variant prompted testing of female siblings and identification of an affected sister. In a second family, the family history suggestive of possible sex-limited transmission prompted analysis of the MAP3K1 gene followed by identification of an affected sister.
Patient 1 is a 6-year-old European Caucasian/Hispanic female who was diagnosed with 46,XY DSD in the neonatal period. Amniocentesis for advanced maternal age revealed a 46,XY fetal karyotype, which was discordant from phenotypic sex noted at birth. Patient 1 had female genitalia at birth, but developed clitoromegaly, first noticed around age 1 year. She presented to our clinic at the age of 4 for further evaluation and management due to parental concerns of progressive clitoral enlargement.
Physical examination was significant for clitoromegaly, with a length of 2.5 cm and width of 0.8 cm, absent labia minora, a low confluence urogenital sinus with absent hymenal tissue, and a 1 cm gonad palpable in the right inguinal canal. A pelvic ultrasound showed bilateral hypoechoic masses within the subcutaneous soft tissues underlying the labia, which were thought to represent gonadal streaks. A uterus was not visualized.
Laboratory studies revealed normal gonadotropins, undetectable gonadal sex steroids, and AMH in the normal male range, indicating the presence of testicular tissue (Table 1) Following interdisciplinary assessment of patient 1, karyotypes were obtained on her three older sisters and one of them, 10-year-old patient 2 was found to have a 46,XY karyotype and the familial MAP3K1 variant (Figure 1a) . Unlike her sister, she had typical external female genitalia, including labia majora, labia minora, clitoris, hymenal opening, and urethra.
Ultrasound of the pelvis showed a rudimentary uterus and small 1 cm gonads bilaterally. Laboratory studies revealed elevated gonadotropins, undetectable gonadal sex steroids, and undetectable AMH, consistent with gonadal failure (Table 1) (Table 1) ; thus, her clinical picture, radiology studies, and laboratory assessment were consistent with complete gonadal dysgenesis. She underwent laparoscopic bilateral gonadectomy at age 16 and the pathological evaluation revealed bilateral streak gonads without any malignant transformation. Wolffian remnants and fallopian tubes were also identified.
Her sister, patient 4, is a 15-year-old female who presented after her sister's diagnosis with primary amenorrhea and minimal breast development. Her karyotype was 46,XY; however, unlike her sister, she had clitoromegaly, which was present since birth. Her physical examination was significant for a clitoris 2 cm in length and 0.6 cm in width and typical labia majora, labia minora, hymen, and urethra. A pelvic ultrasound and MRI demonstrated a prepubertal uterus and 2 cm left gonad. The right gonad was not visualized. Laboratory evaluation revealed elevated gonadotropins, detectable but low gonadal sex steroids, and undetectable AMH, consistent with gonadal failure (Table 1) 
| Patient 5
Patient 5 is a 3-year-old African-American female referred for evaluation of clitoromegaly that was first appreciated at 6 months of age. Physical examination noted an enlarged clitoris that was 3 cm long and 1.5 cm wide and minimal labia minora. The external genitalia were otherwise typical female and gonads were not palpable. Pelvic ultrasound revealed a uterus and bilateral gonadal tissue located in the adnexal regions. Laboratory evaluation showed a normal 46,XY karyotype with FISH positive for SRY, slightly elevated testosterone for female, slightly increased FSH level, and low AMH (Table 1 ). The presentation was most consistent with a diagnosis of partial gonadal dysgenesis. Family history was noncontributory. SNP chromosomal microarray did not detect any copy number variations.
Whole exome sequencing was performed and revealed a variant of uncertain significance in the MAP3K1 gene (c.2291T>G; p.L764R). This variant was not reported in the ExAC, 1000 genomes, or dbSNP databases.
It was classified as possibly damaging by PolyPhen2 and deleterious by SIFT. The patient's unaffected mother was also found to carry the variant.
Bilateral gonadectomy was performed, and pathology showed a right dysgenetic testicle with seminiferous tubules in the tunica and a left ovotestis with predominantly testicular differentiation and focal ovarian fibrous stroma. There was marked atrophy with mainly Sertoli only tubules and thick basement membranes. No germ cell neoplasia or gonadoblastoma was identified. There were both Mullerian (fallopian tubes) and Wollfian duct (epididymis-like) structures present.
| Patient 6
Patient 6 presented at 16 years of age as a tall (180 cm; >99th centile) African American female with amenorrhea, absent breast development, normal pubic and axillary hair, typical female external genitalia, and a 46,XY karyotype. The family history was noncontributory. Laboratory evaluation ruled out steroidogenic disorders, showed an elevated LH and FSH, and Pearlman et al. (2010) . At the time of presentation, the patient was experiencing gender dysphoria from the assigned gender of rearing and is in the process of transitioning from female to male.
| DISCUSSION
Sex-specific gonadal development starts with the formation of the bipotential gonad, which differentiates into an ovary or testis. This process is dependent on the activation of the ovary-specific pathway or the testis-specific pathway. Transcription factors (SRY, SOX9, SOX3, NR0B1, WT1, DMRT1, GATA4, NR5A1) and signaling molecules (WNT4, FGF9, DHH, RSPO1, β-catenin) participate in regulatory networks to modulate these antagonistic pathways (Eggers, Ohnesorg, & Sinclair, 2014; Loke et al., 2014; Ono & Harley, 2013; Ostrer, 2014 and FGFR2, that drive the male-specific pathway in a feed-forward loop, while blocking ovarian development by destabilizing β-catenin (Cool & Capel, 2009; Ostrer, 2014) . Increased p38 and ERK1/2 phosphorylation due to MAP3K1 variants also results in increased expression of β-catenin (CTNNB1) and its downstream target, FOXL2, which by unknown mechanisms suppresses the SOX9/FGF9 feed-forward loop (Eggers et al., 2014; Ostrer, 2014) . Even though we were not able to perform functional studies, the presence of missense variants in one family and two sporadic cases and duplication of a single amino acid in a second family could be consistent with a gain of function effect on the pathway, similar to previously reported pathogenic MAP3K1 variants.
The pattern of inheritance of previously reported MAP3K1 pathogenic variants is autosomal dominant and sex-limited based on familial cases (Ostrer, 2014; Pearlman et al., 2010) . One family from France, of European descent, included six 46,XY females with complete or partial gonadal dysgenesis, three of whom had gonadal tumors (Pearlman et al., 2010) . In this family, there were also four affected males with 46,XY DSD who had genital abnormalities including first-degree hypospadias with chordee and perineal hypospadias. Affected individuals were found to have a c.634-8T>A variant, which resulted in aberrant splicing and segregated with the phenotype. MAP3K1 pathogenic variants were also identified in another family from New Zealand, which included five 46,XY females with complete gonadal dysgenesis, and in two out of 11 unrelated sporadic cases of 46,XY complete gonadal dysgenesis (Pearlman et al., 2010) . In the original two families, there were eight and four obligate unaffected female carriers, respectively. Four sequence variants in the MAP3K1 gene were identified a cohort of 10 Indian patients with 46,XY DSD and negative testing for SRY, SF1, and DHH pathogenic variants. However, all of the identified MAP3K1 variants were found in dbSNP and in the ExAC database (rs702689, rs3822625, rs832575, rs34869245); thus, their pathogenicity in the reported cases is questionable (Das, Rahate, Mehta, Gawde, & Tamhankar, 2013) . In a study by Baxter et al. (2015) , MAP3K1 variants were identified in four sporadic cases with 46,XY DSD. Two patients were females with 46,XY complete gonadal dysgenesis, one patient had 46,XY ovotesticular DSD with ambiguous genitalia, and one patient was a male with 46,XY DSD and complex ambiguous genitalia (perineal hypospadias, small phallus, bifid scrotum, penoscrotal transposition, and no Müllerian structures) ( | 257 (Baxter et al., 2015) . Eggers et al. (2016) (Eggers et al., 2016) . A summary of reported cases is presented in Table 2 . Taken together, these prior studies suggested that pathogenic MAP3K1 variants explain 10-18% of 46,XY DSD and in particular, individuals with complete or partial gonadal dysgenesis.
Here, we report six cases of 46,XY DSD with likely pathogenic MAP3K1 variants in four unrelated families with phenotypes ranging from complete to partial gonadal dysgenesis. In two families, diagnosis of the proband led to identification of 46,XY DSD in a female sibling.
The subjects presented in this report underwent gonadectomy given the increased risk of gonadal tumors in gonadal dysgenesis (Liu et al., 2014; Wolffenbuttel et al., 2016) , and one of six patients demon- additional individuals with pathogenic MAP3K1 variants, the four families described in this report represent 28% of our patient population with a diagnosis of complete or partial gonadal dysgenesis, which is higher than the previously reported findings (Baxter et al., 2015; Eggers et al., 2016; Pearlman et al., 2010 
